Abstract
Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death (ICD), discuss the key factors that dictate the ability of dying cells to drive an adaptive immune response, summarize experimental assays that are currently available for the assessment of ICD in vitro and in vivo, and formulate guidelines for their interpretation.
| Original language | English (US) |
|---|---|
| Article number | e000337 |
| Journal | Journal for ImmunoTherapy of Cancer |
| Volume | 8 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 9 2020 |
Keywords
- immunology
- molecular biology
- oncology
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Molecular Medicine
- Oncology
- Pharmacology
- Cancer Research
Access to Document
Fingerprint Dive into the research topics of 'Consensus guidelines for the definition, detection and interpretation of immunogenic cell death'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. / Galluzzi, Lorenzo; Vitale, Ilio; Warren, Sarah; Adjemian, Sandy; Agostinis, Patrizia; Martinez, Aitziber Buqué; Chan, Timothy A.; Coukos, George; Demaria, Sandra; Deutsch, Eric; Draganov, Dobrin; Edelson, Richard L.; Formenti, Silvia C.; Fucikova, Jitka; Gabriele, Lucia; Gaipl, Udo S.; Gameiro, Sofia R.; Garg, Abhishek D.; Golden, Encouse; Han, Jian; Harrington, Kevin J.; Hemminki, Akseli; Hodge, James W.; Hossain, Dewan Md Sakib; Illidge, Tim; Karin, Michael; Kaufman, Howard L.; Kepp, Oliver; Kroemer, Guido; Lasarte, Juan Jose; Loi, Sherene; Lotze, Michael T.; Manic, Gwenola; Merghoub, Taha; Melcher, Alan A.; Mossman, Karen L.; Prosper, Felipe; Rekdal, Øystein; Rescigno, Maria; Riganti, Chiara; Sistigu, Antonella; Smyth, Mark J.; Spisek, Radek; Stagg, John; Strauss, Bryan E.; Tang, Daolin; Tatsuno, Kazuki; Van Gool, Stefaan W.; Vandenabeele, Peter; Yamazaki, Takahiro; Zamarin, Dmitriy; Zitvogel, Laurence; Cesano, Alessandra; Marincola, Francesco M.
In: Journal for ImmunoTherapy of Cancer, Vol. 8, No. 1, e000337, 09.03.2020.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
AU - Galluzzi, Lorenzo
AU - Vitale, Ilio
AU - Warren, Sarah
AU - Adjemian, Sandy
AU - Agostinis, Patrizia
AU - Martinez, Aitziber Buqué
AU - Chan, Timothy A.
AU - Coukos, George
AU - Demaria, Sandra
AU - Deutsch, Eric
AU - Draganov, Dobrin
AU - Edelson, Richard L.
AU - Formenti, Silvia C.
AU - Fucikova, Jitka
AU - Gabriele, Lucia
AU - Gaipl, Udo S.
AU - Gameiro, Sofia R.
AU - Garg, Abhishek D.
AU - Golden, Encouse
AU - Han, Jian
AU - Harrington, Kevin J.
AU - Hemminki, Akseli
AU - Hodge, James W.
AU - Hossain, Dewan Md Sakib
AU - Illidge, Tim
AU - Karin, Michael
AU - Kaufman, Howard L.
AU - Kepp, Oliver
AU - Kroemer, Guido
AU - Lasarte, Juan Jose
AU - Loi, Sherene
AU - Lotze, Michael T.
AU - Manic, Gwenola
AU - Merghoub, Taha
AU - Melcher, Alan A.
AU - Mossman, Karen L.
AU - Prosper, Felipe
AU - Rekdal, Øystein
AU - Rescigno, Maria
AU - Riganti, Chiara
AU - Sistigu, Antonella
AU - Smyth, Mark J.
AU - Spisek, Radek
AU - Stagg, John
AU - Strauss, Bryan E.
AU - Tang, Daolin
AU - Tatsuno, Kazuki
AU - Van Gool, Stefaan W.
AU - Vandenabeele, Peter
AU - Yamazaki, Takahiro
AU - Zamarin, Dmitriy
AU - Zitvogel, Laurence
AU - Cesano, Alessandra
AU - Marincola, Francesco M.
N1 - Funding Information: 78Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France 79ESSA Pharmaceuticals, South San Francisco, California, USA 80Refuge Biotechnologies, Menlo Park, California, USA Acknowledgements LG is supported by a Breakthrough Level 2 grant from the US Department of Defense (DoD), Breast Cancer Research Program (BRCP) (#BC180476P1), by a startup grant from the Dept. of Radiation Oncology at Weill Cornell Medicine, by industrial collaborations with Lytix and Phosplatin, and by donations from Sotio a.s., Phosplatin, and the Luke Heller TECPR2 Foundation. IV is supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC, IG 2017 grant number 20417) and a startup grant from the Italian Institute for Genomic Medicine (Candiolo, Turin, Italy) and Compagnia di San Paolo (Turin, Italy). Funding Information: Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Competing Interests LG has provided/provides remunerated consulting to AstraZeneca, Boehringer Ingelheim, Inzen and the Luke Heller TECPR2 Foundation, serves on advisory boards for Boehringer Ingelheim and OmniSEQ, has received research support from Lytix Biopharma and Phosplatin, and is an inventor on a patent concerning the use of caspase inhibitors for cancer therapy. TAC is a co-founder of Gritstone Oncology, holds equity in An2H and Gritstone Oncology, has served as an advisor for Bristol-Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca, and An2H, has received grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai, holds ownership of intellectual property on using tumor mutation burden to predict immunotherapy response, with pending patent, which has been licensed to PGDx. GC has received honoraria for consultations or presentations by Roche, Genentech, BMS, AstraZeneca, Sanofi-Aventis, Nextcure and GeneosTx, has received grants, research support or is coinvestigator in clinical trials from/by BMS, Celgene, Boehringer Ingelheim, Roche, Iovance and Kite, has patents in the domain of antibodies and vaccines targeting the tumor vasculature as well as technologies related to T-cell expansion and engineering for T-cell therapy, and holds patents around TEM1 antibodies and receives royalties from the University of Pennsylvania regarding technology licensed to Novartis. SD has received compensation for consultant/advisory services from AstraZeneca, EMD Serono, Lytix Biopharma, and Mersana Therapeutics, and has received research support from Lytix Biopharma and Nanobiotix. ED has received personal fees from Accuray, Amgen, AstraZeneca, Merck Serono, and Roche, and has received grants from AstraZeneca, Boehringer, BMS, Lilly, Merck Serono, MSD, Roche and Servier. DD is an employee and options holder of Calidi Biotherapeutics. USG has served on the advisory boards for AstraZeneca, and BMS, and has received funding for IITs from MSD and AstraZeneca. AH is shareholder in Targovax ASA, and employee and shareholder in TILT Biotherapeutics Ltd. DH is employed by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. HLK is an employee of Replimune, Inc. OK is a cofounder of Samsara Therapeutics. GK has been holding research contracts with Bayer Healthcare, Genentech, Glaxo Smyth Kline, Institut Mérieux, Kaleido, Lytix Pharma, Nucana, Oncolinx, PharmaMar, Samsara, Sotio and Vasculox, serves on the Board of Directors of the Bristol Myers Squibb Foundation France, and is a scientific co-founder of everImmune and Samsara Therapeutics. SL has acted as non-compensated consultant for AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche-Genentech and Seattle Genetics, and as compensated consultant (via her institution) for Aduro Biotech, and receives research funding from BMS, Eli Lilly, Merck, Novartis, Puma Biotechnology, Pfizer and Roche-Genentech, MTL serves as an advisor for Checkmate, iRepetoire, Nurix, Myst, Instilbio, and Torque. TM is consultant for Leap Therapeutics, Immunos Therapeutics and Pfizer, co-founder of Imvaq therapeutics, has equity in Imvaq therapeutics, reports grants from Bristol-Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals, Peregrine Pharmeceuticals, Adaptive Biotechnologies, Leap Therapeutics, Aprea, and is inventor on patent applications related to work on oncolytic viral therapy, alphavirus-based vaccines, neo-antigen modeling, CD40, GITR, OX40, PD-1 and CTLA-4. ØR is an employee and shareholder in Lytix Biopharma. MR serves as an advisor for Gelesis, MillBo, Casillo, has research contracts with fKraftHeinz, Gelesis, AlfaSigma and is founder of Postbiotica. JS is a permanent member of the scientific advisory board and owns stocks of Surface Oncology. TY has received research support from Lytix Biopharma and Phosplatin. DZ reports consulting fees from Merck, Synlogic Therapeutics, Tesaro, Trieza Therapeutics, and Western Oncolytics, and is an inventor on a patent concerning the use of Newcastle Disease Virus for cancer therapy. LZ has served on the Board of Directors of Transgene and on advisory boards for EpiVax, Lytix Biopharma, NeoVax, Transgene, Vedanta, has research contracts with BMS, GSK, Incyte, Innovate Bopharma, Kaleido, Pilege, and Transgene, and is founder of everImmune.p, li { white-space: pre-wrap; }
PY - 2020/3/9
Y1 - 2020/3/9
N2 - Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death (ICD), discuss the key factors that dictate the ability of dying cells to drive an adaptive immune response, summarize experimental assays that are currently available for the assessment of ICD in vitro and in vivo, and formulate guidelines for their interpretation.
AB - Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death (ICD), discuss the key factors that dictate the ability of dying cells to drive an adaptive immune response, summarize experimental assays that are currently available for the assessment of ICD in vitro and in vivo, and formulate guidelines for their interpretation.
KW - immunology
KW - molecular biology
KW - oncology
UR - http://www.scopus.com/inward/record.url?scp=85081610705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081610705&partnerID=8YFLogxK
U2 - 10.1136/jitc-2019-000337
DO - 10.1136/jitc-2019-000337
M3 - Review article
C2 - 32209603
AN - SCOPUS:85081610705
VL - 8
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
SN - 2051-1426
IS - 1
M1 - e000337
ER -